Novel Stool mRNA Biomarkers Show Promise for Non-Invasive Colorectal Cancer Detection
Key Insights
El Capitan Biosciences (search) researchers published a study in Scientific Reports demonstrating a bioinformatics-guided approach to identify mRNA biomarkers (search) in stool for colorectal cancer (search) detection.
The multi-gene mRNA panel achieved an AUC of 0.94 for colorectal cancer (search) detection with 75.5% sensitivity and 95% specificity in a 114-sample validation study.
For advanced adenomas (search), the panel showed superior performance compared to current tests, achieving 55.8% sensitivity versus the 10-40% sensitivity of fecal immunochemical tests (search).
A peer-reviewed study published in Scientific Reports demonstrates a novel bioinformatics approach for identifying messenger RNA biomarkers in stool that could significantly improve non-invasive detection of colorectal cancer (search) and its precancerous lesions. The research, conducted by scientists from El Capitan Biosciences (search) and partners, achieved robust diagnostic performance that outperforms current screening methods for advanced adenomas (search).
Bioinformatics-Driven Biomarker Discovery
The research team employed a systematic two-step methodology to identify optimal mRNA biomarkers (search). First, they conducted a computational screen of public tissue databases, ranking genes based on their differential expression in colorectal cancer (search) versus normal colon tissue. The top candidate genes from this in silico analysis were then validated using RT-qPCR (search) on 114 clinical stool samples, including 33 colorectal cancer cases, 28 advanced adenomas (search), and 53 controls.
This approach leverages large public genomic datasets to effectively prioritize biomarker candidates for costly clinical validation, potentially streamlining the development process for next-generation diagnostics.
Superior Diagnostic Performance
The combined multi-gene mRNA panel demonstrated exceptional diagnostic accuracy. For colorectal cancer (search) detection, the panel achieved an Area Under the Curve of 0.94, with 75.5% sensitivity and 95% specificity when discriminating cancer patients from controls.
Perhaps more significantly, the panel showed promising results for detecting advanced adenomas (search), which are frequently missed by current non-invasive screening tests. The biomarker panel achieved an AUC of 0.83 for advanced adenoma detection, with 55.8% sensitivity and 92.6% specificity. This sensitivity represents a substantial improvement over fecal immunochemical tests (search), which report only 10-40% sensitivity for advanced adenomas.
Addressing Critical Screening Gaps
"Improving the detection of precancerous lesions is a critical unmet need in colorectal cancer (search) screening, as it allows for intervention before cancer develops," said Wenying Pan, PhD, Co-founder and CEO of El Capitan Biosciences (search). The company has established a proprietary platform for extracting human-host RNA from stool and developed a whole-transcriptome biomarker discovery platform.
According to Pan, this platform addresses a critical gap in the industry's understanding of the complete human stool transcriptome, providing pharmaceutical companies researching intestinal diseases with comprehensive omics data perspectives. When combined with unique bioinformatics algorithms, the platform enables deep mining of novel targets and biomarkers, potentially accelerating drug target discovery and enhancing clinical trial efficiency and success rates.
Clinical Implications and Future Directions
The study's findings suggest that stool-based mRNA biomarkers (search) could offer a more effective approach to colorectal cancer (search) screening, particularly for detecting precancerous lesions that current methods often miss. The ability to identify advanced adenomas (search) with higher sensitivity could enable earlier intervention and potentially reduce colorectal cancer incidence through improved screening programs.
El Capitan Biosciences (search), a California-based company focused on gut multi-omics biomarker discovery, continues to develop products for screening and diagnosing gastrointestinal diseases. Their proprietary RNA extraction methods and whole-transcriptome discovery platform aim to enhance clinical solutions for early disease detection, precision medication, and disease monitoring in intestinal disorders.
The investigational approach described in the study is not cleared or approved by the U.S. FDA and is not currently available for clinical use. The research is published with DOI: 10.1038/s41598-025-13074-4.